1. Japan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
PHC Holdings Corp.

PHC Holdings Corp.

7.40
EUR
0.00
(0.00%)
752.75MMarket Cap
Nov 11Next Earn
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
1,570.72
2,295.61
2,698.68
2,848.3
2,858.65
2,812.97
2,866.88
2,881.89
- -
Basic EPS, GAAP
130.11
44.43
149.06
-70.78
-25.83
-102.47
83.12
3.89
- -
Free Cash Flow per Basic Share
227.54
203.19
314.74
328.94
79.08
212.02
240.48
263.87
- -
Dividend per Share
- -
- -
- -
- -
73.75
71.85
38.98
41.96
- -
Book Value per Share
531.61
572.44
871.74
1,092.32
1,101.33
1,106.98
1,122.35
1,277.89
1,277.89
Tangible Book Value per Share
-1,018.68
-2,004.29
-1,687.74
-1,303.28
-1,219.55
-1,274.21
-1,153.03
-1,060.98
-1,060.98
Basic Weighted Avg Shares
119
119
113
120
125
126
126
126
126
Sales/Revenue/Turnover
186,546
272,637
306,071
340,452
356,434
353,900
361,593
364,403
- -
Operating Margin (%)
12.19
4.86
5.86
2.51
5.76
0.49
6.35
6.2
- -
Depreciation Expense
16,157
26,917
30,371
31,077
29,015
27,933
27,871
27,119
- -
Net Income, GAAP
15,453
5,277
16,906
-8,460
-3,221
-12,892
10,484
492
- -
Effective Tax Rate (%)
25.24
5.33
26.15
376.48
1,803.35
- -
44.93
96.56
- -
Profit Margin (%)
8.28
1.94
5.52
-2.48
-0.9
-3.64
2.9
0.14
- -
Working Capital
35,020
28,741
-253,530
78,616
67,741
40,449
32,235
-13,454
-13,454
LT Debt
171,861
306,879
67
280,685
262,403
248,123
220,982
156,303
156,303
Total Equity
65,249
70,295
107,560
136,064
138,827
139,164
141,171
160,880
160,880
Return on Invested Capital (%)
- -
3.77
3.09
-5.13
-77.33
- -
3.01
0.2
- -
Return on Capital (%)
- -
3.82
6.04
-6.74
-79.5
- -
3.29
0.34
- -
Return on Common Equity (%)
- -
7.79
19.07
-6.98
-2.36
-9.29
7.46
0.32
- -

Capital Structure

JPY

•

in mil. unless spec.
Jun'26
Sep'26
Mar'26
ST Debt
- -
245,011
78,254
LT Borrowings
- -
2,680
156,303
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
127
127
127
Market Capitalization
115,952
121,834
138,075

Working Capital

JPY

•

in mil. unless spec.
Jun'26
Sep'26
Mar'26
Total Current Assets
- -
169,056
176,180
Cash, Cash Equivalents & STI
- -
36,853
44,745
Accounts Receivable, Net
- -
65,370
70,283
Inventories
- -
57,897
53,095
Total Current Liabilities
- -
347,637
189,634
Payables & Accruals
- -
- -
- -
ST Debt
- -
245,011
78,254
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
8.83%
13.96%
Free Cash Flow
- -
25.89%
10%
Net Income, GAAP
- -
-37.67%
-95.31%
Sales/Revenue/Turnover
- -
3.63%
0.78%
Total Cash Common Dividend
- -
- -
7.93%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
81,325
85,493
89,864
97,217
353,900
2025
- -
- -
- -
- -
361,593
2026
- -
- -
- -
- -
364,403

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-25.49
5.9
-69.07
-13.78
-102.47
2025
- -
- -
- -
- -
83.12
2026
- -
- -
- -
- -
3.89

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
33.27
2.67
33.69
2.27
71.85
2025
- -
- -
- -
- -
38.98
2026
- -
- -
- -
- -
41.96

Company Description

Company Profile APIChatGPT
CEO
Kyoko Deguchi
Full Time Employees
8,647
Sector
Health technology
Industry
Medical specialties
Address
Dai-ichi Life Hibiya First Tokyo Japan 100-8403
IPO Date
Oct 14, 2021
Website
phchd.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
PHC Holdings Corporation PHC Holdings Corporation (6523.T), headquartered in Tokyo, Japan and founded in 2014 as an independent entity following a management buyout from Hitachi Ltd., engages primarily in the development, manufacture, and sale of healthcare devices, healthcare IT solutions, and life science products and services through its subsidiaries. The company operates across three main segments: Diabetes Management, offering blood glucose monitoring systems, continuous glucose monitoring systems such as Eversense, point-of-care testing products, and digital diabetes management applications marketed in over 100 countries; Healthcare Solutions, providing electronic medical record systems, receipt computers, electronic medication history systems, pharmacy management tools, telemedicine platforms, and clinical laboratory diagnosis services mainly in Japan; and Diagnostics & Life Sciences, encompassing research equipment like low-temperature freezers, CO2 incubators, sample preservation systems, cell culture devices, cancer pathology solutions including tissue processors, microscope slides, consumables, and dyeing reagents from Epredia Holdings Ltd., as well as in vitro diagnostic reagents, immunoassay analyzers such as PATHFAST, and drug development support products. PHC Holdings maintains a global footprint with key operations in Japan, North America, Europe, and Asia, targeting healthcare providers, clinics, hospitals, pharmacies, research institutions, universities, and pharmaceutical companies. Recent developments include the integration of subsidiaries Wemex Corporation and Wemex Healthcare Systems Corporation in October 2025 to enhance healthcare IT capabilities in Japan; a memorandum of understanding signed by subsidiary Ascensia Diabetes Care in September 2025 with Senseonics Inc. to transfer commercial activities of the Eversense continuous glucose monitoring system; the launch of non-fluorine large-capacity freezer-equipped pharmaceutical refrigerators MPR-N650FH and MPR-N650FSH in November 2025 for improved drug storage; and the release of the Integrated Report 2025 alongside a revised full-year performance forecast in November 2025.